{"id":"placebo-pcb","safety":{"commonSideEffects":[{"rate":null,"effect":"Nocebo effects (adverse events attributed to placebo)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebo effects arise from complex neurobiological mechanisms including expectation, conditioning, and endogenous neurotransmitter release. In clinical trials, placebos serve as control comparators to distinguish true drug efficacy from placebo response. The magnitude of placebo effect varies by condition, route of administration, and patient belief.","oneSentence":"Placebo produces therapeutic effects through patient expectation and the psychobiological response to receiving treatment, rather than through a pharmacologically active ingredient.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:51:40.031Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Control arm in phase 3 clinical trials (non-therapeutic use)"}]},"trialDetails":[{"nctId":"NCT00370240","phase":"PHASE4","title":"Chlorhydrate of Ropivacaine and Breast Cancer Surgery","status":"COMPLETED","sponsor":"Institut Curie","startDate":"2006-09","conditions":"Breast Neoplasms, Pain,Postoperative","enrollment":260},{"nctId":"NCT07095049","phase":"PHASE1","title":"Safety, Tolerability, and Systemic Exposure of Apo-Si- K170A-C76 in Healthy Volunteers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Interna Therapeutics Ltd.","startDate":"2024-09-04","conditions":"SARS-CoV-2 (COVID-19) Infection","enrollment":56},{"nctId":"NCT07027020","phase":"PHASE3","title":"Efficacy of Intravesical Oxybutynin in Children With Neurogenic Bladder Dysfunction","status":"NOT_YET_RECRUITING","sponsor":"Central Hospital, Nancy, France","startDate":"2025-09","conditions":"Spina Bifida","enrollment":60},{"nctId":"NCT05159830","phase":"PHASE2","title":"Cannabidiol for Reducing Drinking in Alcohol Use Disorder","status":"RECRUITING","sponsor":"Hôpital le Vinatier","startDate":"2024-10-25","conditions":"Alcohol Use Disorder","enrollment":76},{"nctId":"NCT04760613","phase":"PHASE1, PHASE2","title":"CBD for Chronic Radicular Pain on Chronic Opioid Therapy (COT)","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2022-02-03","conditions":"Radiculopathy","enrollment":14},{"nctId":"NCT06383689","phase":"NA","title":"Placebo Optimization of the Presurgical Long-term Video-EEG Monitoring","status":"RECRUITING","sponsor":"University Hospital, Bonn","startDate":"2024-05-13","conditions":"Symptomatic Epilepsy","enrollment":90},{"nctId":"NCT05785689","phase":"PHASE4","title":"Autonomous Nervous System Regulated Paediatric Anaesthesia With Dexmedetomidine or Placebo","status":"UNKNOWN","sponsor":"University of Southern Denmark","startDate":"2023-04-01","conditions":"Postoperative Confusion, Postoperative Delirium, Postoperative Pain, Acute","enrollment":220},{"nctId":"NCT02947581","phase":"PHASE3","title":"Sub Arachnoid Neurocysticercosis Treatment Outcome (SANTO)","status":"TERMINATED","sponsor":"Universidad Peruana Cayetano Heredia","startDate":"2016-11-14","conditions":"Neurocysticercosis","enrollment":107},{"nctId":"NCT01497249","phase":"NA","title":"Assessing Fermentability of a Dietary Fiber","status":"COMPLETED","sponsor":"Clinical Nutrition Research Center, Illinois Institute of Technology","startDate":"2011-12-01","conditions":"Nutritional Intervention","enrollment":29},{"nctId":"NCT02613897","phase":"NA","title":"ESR-15-11293 - Saxa/Dapa, Safety and Efficacy Study","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2016-01","conditions":"Diabetes Mellitus, Type 2","enrollment":56},{"nctId":"NCT02057757","phase":"PHASE2","title":"Nitazoxanide Versus Placebo for the Treatment of Hospitalized Subjects With Severe Acute Respiratory Illness","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2014-02","conditions":"Severe Acute Respiratory Illness","enrollment":260},{"nctId":"NCT03205033","phase":"PHASE2","title":"Melatonin as a Circadian Clock Regulator, Neuromodulator and Myelo-protector in Adjuvant Breast Cancer Chemotherapy","status":"COMPLETED","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2016-01","conditions":"Sleep Disorders, Circadian Rhythm, Depression, Genotoxicity","enrollment":36},{"nctId":"NCT00710385","phase":"PHASE3","title":"Abuse Liability of Suboxone Versus Subutex","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2007-09","conditions":"Opioid-related Disorders","enrollment":19},{"nctId":"NCT00723177","phase":"PHASE2","title":"Phase IIa Study of AV411, a Glial Activation Inhibitor, for Opioid Withdrawal","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2008-10","conditions":"Opioid-Related Disorders","enrollment":30},{"nctId":"NCT02096575","phase":"NA","title":"Nitrous Oxide for Pain Management of First Trimester Surgical Abortion","status":"COMPLETED","sponsor":"University of New Mexico","startDate":"2012-08","conditions":"Abortion in First Trimester","enrollment":140},{"nctId":"NCT01395784","phase":"PHASE2","title":"Effects of Pioglitazone, a PPARgamma Receptor Agonist, on the Abuse Liability of Oxycodone","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2010-08","conditions":"Opioid Abuse","enrollment":32},{"nctId":"NCT02194023","phase":"PHASE2","title":"Clinical Effects of Two New Chlorhexidine Digluconate Formulations: 0.12% and 0.03%.","status":"COMPLETED","sponsor":"Universitat Internacional de Catalunya","startDate":"2011-09","conditions":"Dental Plaque, Side Effects","enrollment":200},{"nctId":"NCT02007408","phase":"NA","title":"Comparison of Lidocaine Spray and Paracervical Block Application for Pain Relief During First-trimester Surgical Abortion: a Randomized, Double-blind, Placebo-controlled Trial","status":"COMPLETED","sponsor":"Kayseri Education and Research Hospital","startDate":"2013-05","conditions":"Pain Score","enrollment":108}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":51,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["PCB or 0 mg","0 mg"],"phase":"phase_3","status":"active","brandName":"Placebo (PCB)","genericName":"Placebo (PCB)","companyName":"New York State Psychiatric Institute","companyId":"new-york-state-psychiatric-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Placebo produces therapeutic effects through patient expectation and the psychobiological response to receiving treatment, rather than through a pharmacologically active ingredient. Used for Control arm in phase 3 clinical trials (non-therapeutic use).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}